Bearish
0
Neutral
8
Bullish
6
Bearish
15
Neutral
8
Bullish
23
Bearish
15
Neutral
0
Bullish
17
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q2 FY26
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Market Cap
₹ 373 Cr
P/E
28.20
Analyst/Investor Meet
14 hours ago
Investor Meeting Scheduled for December 22, 2025
Fabtech Technologies Cleanrooms Limited has announced an analyst/investor meeting set for December 22, 2025, at 4:00 PM IST, to be held virtually.
Subsidiary Incorporation
15 hours ago
Incorporation of Foreign Wholly Owned Subsidiary
Fabtech Technologies Cleanrooms Limited has approved the formation of a foreign wholly owned subsidiary in the United Arab Emirates.
Board Meeting Outcome
15 hours ago
Approval for Foreign Wholly Owned Subsidiary
Fabtech Technologies Cleanrooms Limited's Board has approved the incorporation of a foreign wholly-owned subsidiary in the UAE.
Board Meeting Outcome
18 hours ago
Board Meeting Approves Foreign Subsidiary Incorporation
The Board of Fabtech Technologies Cleanrooms Limited approved the incorporation of a foreign wholly-owned subsidiary in the UAE during their meeting on December 17, 2025.
Corporate Action
18 hours ago
Incorporation of Wholly Owned Subsidiary in UAE
Fabtech Technologies Cleanrooms Limited has received approval from its Board to incorporate a wholly-owned subsidiary in the United Arab Emirates.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
373 Cr
Low Risk
28.2
30.7
0.5
4.0
470.00
161.50
Sales CAGR
1Y
54.05%
3Y
9.08%
5Y
10.22%
10Y
—
Profit CAGR
1Y
123.35%
3Y
55.59%
5Y
25.09%
10Y
—
ROE
TTM
12.57%
3Y
13.96%
5Y
11.77%
10Y
—
ROCE
TTM
13.83%
3Y
18.99%
5Y
16.15%
10Y
—
Performance
MARKET LEADER
Valuation
OVERVALUED
Growth
EXCEPTIONAL
Profitability
MODERATE MARGIN
Technicals
Bullish
Risk
MODERATE RISK